- Home
- PMO vs ESPR Comparison
PMO vs ESPR Comparison
Compare PMO & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PMO | ESPR |
|---|---|---|
| Founded | 1993 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 294.3M | 898.5M |
| IPO Year | N/A | 2013 |
Fundamental Metrics
Financial Performance| Metric | PMO | ESPR |
|---|---|---|
| Price | $10.41 | $4.03 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $6.67 |
| AVG Volume (30 Days) | 99.0K | ★ 5.6M |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | ★ 4.10% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.42 | N/A |
| Revenue | N/A | ★ $303,802,000.00 |
| Revenue This Year | N/A | $26.11 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $24.38 | ★ N/A |
| Revenue Growth | N/A | ★ 2.83 |
| 52 Week Low | $8.57 | $0.69 |
| 52 Week High | $10.68 | $4.13 |
Technical Indicators
Market Signals| Indicator | PMO | ESPR |
|---|---|---|
| Relative Strength Index (RSI) | 46.61 | 61.22 |
| Support Level | $10.31 | $3.87 |
| Resistance Level | $10.53 | $4.13 |
| Average True Range (ATR) | 0.09 | 0.20 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 29.03 | 79.00 |
Price Performance
Historical ComparisonAbout PMO Putnam Municipal Opportunities Trust
Putnam Municipal Opportunities Trust is a non-diversified closed-end management investment company. It seeks to provide as high a level of current income free from federal income tax as Putnam Management believes is consistent with the preservation of capital. The fund invests in healthcare, utilities, transportation, tax bonds, local debt, state debt, and education.
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.